Contact Sales
Contact Service
Request A Quote
Newsroom / Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development

Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development

Read Press Release

Related Posts

  • Newsroom

Asahi Kasei Bioprocess to Unveil THESYS™ ACS ERGO Synthesis Column at TIDES USA

Learn More
  • Newsroom

Accelerating R&D Innovation, Sustainability and Production Capacity for 2030 – Expansion of Asahi Kasei Bioprocess America Facilities by Mid-2023

Learn More
  • Newsroom

Asahi Kasei Bioprocess to Showcase Award-winning MOTIV™ Buffer Management Technology for Pharmaceutical Manufacturing at ACHEMA 2022

Learn More

SUSTAINABILITY

Asahi Kasei Bioprocess plays a significant role in contributing to life and living for people around the world. Learn how we strive to provide a sustainable future.

Engage

Newsletter Sign-Up